Skip to content

Validation and Standardisation of a Pool of Simplified Evaluation Aimed to the Diagnoses of Aphasic Disorders and Adapted to the Patients Suffering an Acute Phase of Stroke

Validation and Standardisation of a Pool of Simplified Evaluation Aimed to the Diagnoses of Aphasic Disorders and Adapted to the Patients Suffering an Acute Phase of Stroke

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02548481
Acronym
BESTA-AVC
Enrollment
395
Registered
2015-09-14
Start date
2015-11-01
Completion date
2021-06-01
Last updated
2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Brief summary

Every year in France, from 100 000 to 145 000 people are affected by a stroke. 75% patients survived with aftereffects, in particular aphasic disorders. A sketch of a new tool called BESTA aiming to a rapid handover to the acute phase post stroke had been worked out. After a meeting, 13 multidisciplinary experts have discussed, adjusted and a new complete tool (BESTA) had been created in order to evaluate the different states of aphasia. The goal of this study is the validation and the standardization of this new BESTA tool.

Interventions

OTHERBESTA scale

BESTA scale is administrated at T0, T1 and T2.

Sponsors

University Hospital, Limoges
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Patients with stroke: * Every patient over 18, * admitted among neuro-vascular unit, * native french speaker, * the level of vigilance is satisfactory in order to allow a speech therapy test. Healthy Volunteers: * Every volunteers over 18, * without any medical history of a stroke or any speech disorders, * native french speaker.

Exclusion criteria

Patients with stroke and Healthy Volunteers : * dementia disease * psychiatric condition * non-equipped deafness * pregnant woman * patient with medical histories of stroke

Design outcomes

Primary

MeasureTime frameDescription
validity of concomitant criterion at T0 versus LAST1 dayT0: the gold standard was determined by the expert group is the LAST screening tool. The tool to be evaluated is the BESTA at T0. However, as written expression is not evaluated in the LAST, only the dimensions and Oral Expression Listening Comprehension of BESTA may actually be faced with LAST scale.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORFrancisco MACIAN, MD

University Hospital, Limoges

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026